Showing 1061-1070 of 20387 results for "".
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
https://reachmd.com/programs/cme/from-evidence-to-action-integrating-emerging-myosin-inhibitors-into-ohcm-treatment-plans/54841/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
https://reachmd.com/programs/cme/redefining-ohcm-care-efficacy-and-safety-of-myosin-inhibitors/54840/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
https://reachmd.com/programs/cme/understanding-igan-fsgs-pathophysiology-and-emerging-therapies/14974/Hear experts discuss how emerging therapies for IgAN and FSGS may achieve proteinuria remission and shape clinical treatment decisions for patients.In Your Waiting Room: The Virtual IBS-C Patient Clinical Experience
https://reachmd.com/programs/cme/in-your-waiting-room-the-virtual-ibs-c-patient-clinical-experience/14955/What else can you do for your patients with IBS-C whose current therapies aren’t enough? Join our experts to explore the stories of 3 patients.How to Identify & Manage Patients with Progressive-Fibrosing ILD
https://reachmd.com/programs/cme/how-to-identify-and-manage-patients-with-progressive-fibrosing-ild/10942/ILD diagnosis is complex and management can be tricky. Hear how to navigate this path and how the patient’s perspective can influence the care plan.Bronchiectasis Update: Diagnostic Innovations and Therapeutic Frontiers
https://reachmd.com/programs/cme/bronchiectasis-update-diagnostic-innovations-and-therapeutic-frontiers/37233/Bronchiectasis is complex, often underdiagnosed, and frequently misunderstood. Explore key contributors to disease progression, including the role of neutrophilic inflammation and neutrophilic serine proteases, and learn to distinguish bronchiectasis from other respiratory conditions and assess patiAmyloid and Tau in Alzheimer’s Disease: Insights into Disease Progression
https://reachmd.com/programs/medical-industry-feature/amyloid-tau-alzheimers-disease-progression/37874/The prevalence of dementia is projected to almost double every 20 years.1 Alzheimer’s disease (AD) is the most common cause of dementia,2 making early diagnosis and management increasingly important. Based on our current understanding of its pathology, AD is an amyloid driven tauopathy3 with biomarkPractical Dermatology Roundtable: The Role of Adjuvant Skin Cleansing and Moisturizing in Treating Psoriasis and Other Inflammatory Diseases, Ch. 6
https://reachmd.com/programs/the-practical-dermatology-roundtable/practical-dermatology-roundtable-the-role-of-adjuvant-skin-cleansing-and-moisturizing-in-treating-psoriasis-and-other-inflammatory-diseases-ch-6/56874/In the sixth installment of this eight-part series, host Ted Lain, MD, MBA, FAAD, and guests Zoe Diana Draelos, MD, and Firas George Hougeir, MD, FAAD, discuss patient adherence, tolerability, and the importance of simple, non-irritating regimens in achieving real-world success.1 Draelos Z, HougeirMenin Inhibitors: Biologic and Clinical Rationale
https://reachmd.com/programs/cme/menin-inhibitors-biologic-and-clinical-rationale/36179/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
https://reachmd.com/programs/cme/tbd/37670/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.